How they work

How Does Semaglutide Work? The Mechanism, Explained Simply

Semaglutide is a lab-modified copy of a gut hormone that tells your pancreas to release insulin, tells your liver to hold back sugar, slows your stomach, and signals fullness to your brain - and the modifications let one dose last about a week.

Last verified September 14, 2026·13 sources cited·Ozempic Wegovy

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Semaglutide is a copy of a hormone your gut already makes, rebuilt in a lab so it lasts about a week instead of about two minutes. Everything it does in the body flows from that one idea.

This article explains the mechanism in plain English: what the original hormone does, what chemists changed, what happens in your pancreas, your stomach and your brain, and why the side effects people talk about are the same mechanism showing up in a less welcome form.

None of this is medical advice. Doses, product choices and whether a GLP-1 medicine is right for you are decisions for you and a healthcare provider.

What is semaglutide actually copying?

The hormone is called GLP-1, short for glucagon-like peptide-1. Cells in the lining of your lower small intestine and colon, called L-cells, release it within minutes of you eating [9].

GLP-1 does four main jobs:

It tells the pancreas to release more insulin, but only when blood sugar is already up.
It tells the pancreas to hold back glucagon, the hormone that pushes the liver to dump stored sugar into the blood.
It slows how quickly the stomach passes food along.
It signals the brain that you have eaten.

Your own GLP-1 is extremely short-lived. An enzyme called DPP-4 clips two amino acids off its front end and switches it off within about two minutes [9]. That is fine for a hormone whose job is to respond to a meal. It is useless as a drug.

FDA labeling describes semaglutide as “a GLP-1 analogue with 94% sequence homology to human GLP-1” [1]. It is a 31-amino-acid peptide - close enough to the real thing to fit the same receptor, different enough to survive.

What did chemists change to make it last a week?

Three modifications, each with a job [10]:

A blocking amino acid at position 8. DPP-4 recognizes an alanine in the second position of the peptide and cuts there. Semaglutide swaps that alanine for alpha-aminoisobutyric acid, an amino acid the body does not normally use. DPP-4 cannot grip it [10].

A fatty tail at position 26. An eighteen-carbon fatty diacid is attached to a lysine through a short chemical spacer. That tail binds reversibly to albumin, the most abundant protein in your blood [10]. The label states that semaglutide is “extensively bound to plasma albumin (>99%)” [1].

A swap at position 34. Lysine becomes arginine, so the fatty tail can only attach at one place rather than two, giving a single uniform product [10].

The albumin binding is the clever part. At any moment, more than 99 out of every 100 semaglutide molecules in your blood are stuck to albumin and effectively parked. Only the small free fraction can reach receptors. As free drug is used up, more is released from the albumin pool. The result is a slow, flat release that keeps working between weekly injections - an elimination half-life of about one week [1][2].

What happens in the pancreas?

This is the effect semaglutide was originally approved for. Ozempic’s label describes it directly: semaglutide “stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner” [1].

“Glucose-dependent” is the phrase that matters. Semaglutide does not force insulin out. It amplifies the pancreas’s response when glucose is already high, and that amplification fades as glucose comes down. That is why semaglutide on its own is unlikely to drive blood sugar dangerously low - and why the label still warns that combining it with insulin or an insulin secretagogue increases hypoglycemia risk [1].

The measured effects in the labeling: fasting glucose about 29 mg/dL lower and two-hour post-meal glucose about 74 mg/dL lower compared with placebo, with both first-phase and second-phase insulin secretion increased and glucagon levels reduced [1].

What happens in the stomach?

Semaglutide slows gastric emptying, mostly in the first hour after a meal. In a 12-week study in people with obesity, first-hour emptying measured by acetaminophen absorption was clearly delayed compared with placebo, with an area-under-the-curve ratio of 0.73, while overall emptying across five hours was similar to placebo [4].

The Ozempic label calls it “a minor delay in gastric emptying in the early postprandial phase” [1].

That single sentence explains a lot of lived experience. Food sitting longer in the stomach flattens the post-meal glucose spike. It also produces early fullness, bloating, reflux and nausea - and it is the reason anesthesiologists now ask about GLP-1 medications before procedures, because food can still be present after a standard fast.

Interestingly, at the higher 2.4 mg weight-management dose studied by Friedrichsen and colleagues, five-hour acetaminophen absorption was only 8% higher than placebo at week 20 and first-hour absorption was not significantly different [3]. That suggests the stomach effect is not the main engine of weight loss at that dose. Which points somewhere else.

What happens in the brain?

Most of semaglutide’s weight effect appears to be a brain effect.

In that same randomized study, adults with obesity taking semaglutide 2.4 mg ate 35% less at a free-access lunch at week 20 than they did on placebo - 1,736 kilojoules versus 2,676, a difference of about 940 kilojoules, or roughly 225 calories, in a single meal [3]. Participants also reported less hunger, more fullness, better control of eating and fewer food cravings [3].

How does a drug that mostly stays bound to albumin in the bloodstream reach the brain at all? Not by crossing the blood-brain barrier in the usual sense. Research in rodents found semaglutide accumulates at circumventricular organs - specific sites where the barrier is naturally leaky by design, so the brain can sample the blood directly [6].

Two of those sites matter most:

The area postrema, in the brainstem. Together with the neighboring nucleus tractus solitarius it forms the dorsal vagal complex. A 2025 paper in Cell Metabolism reported that semaglutide’s effects on energy balance are mediated by a specific population of neurons there [7]. A 2026 paper in Nature Metabolism mapped how semaglutide raises cyclic AMP inside those neurons through both Gs-dependent and Gs-independent routes [8].

The hypothalamus, specifically POMC neurons in the arcuate nucleus. These fire faster when GLP-1 receptors are activated, releasing peptides that act on the melanocortin-4 receptor to suppress food intake [5].

There is also a wire running up from the gut. GLP-1 receptors sit on vagal nerve endings in the stomach and duodenum that sense stretch [5]. A meal plus a GLP-1 drug sends a stronger “we are full” signal up that nerve than the meal alone would.

Rodent work suggests no single one of these pathways is essential on its own - the weight effect is distributed across several of them at once [6].

Why does semaglutide cause nausea and early fullness?

Here is the uncomfortable symmetry. The area postrema is not only where fullness is registered. It is also the brain’s vomiting trigger zone.

So the circuit that makes a meal feel like enough is adjacent to the circuit that makes you feel queasy. Add slowed stomach emptying in the first hour after eating, and you get the classic early-treatment experience: nausea, early fullness, sometimes vomiting or constipation.

This is precisely why every semaglutide product starts low and climbs slowly. The Ozempic injection label, revised May 2026, is explicit that the escalation schedule exists “to reduce the risk of gastrointestinal adverse reactions” [2]. The oral semaglutide label is blunter still: it says the 3 mg Rybelsus and 1.5 mg Ozempic tablet starting doses are “not effective for glycemic control” [13]. Those first weeks are there so your body can adjust, not to treat anything.

Peri-operative consensus guidance makes the same point from another angle: gastrointestinal effects cluster in the first weeks after starting or increasing a long-acting GLP-1 medicine.

Where are GLP-1 receptors in the body?

Beyond the pancreas, GLP-1 receptor messenger RNA has been found in lung, brain, kidney, stomach and heart tissue [11]. Protein-level studies using validated antibodies located the receptor in pancreatic islets, parts of the gastrointestinal tract, the heart’s sinoatrial node and atria, and smooth muscle in the walls of kidney and lung arteries.

Two caveats worth knowing. Human receptor levels are generally low compared with rodents, and the distribution differs between species - rat and mouse lung and thyroid express far more GLP-1 receptor than human tissue does. That species gap is one reason findings in animals do not translate directly to people.

Does semaglutide cause muscle loss as well as fat loss?

In the STEP 1 body-composition substudy, 140 participants had DXA scans at the start and at week 68. In the semaglutide group, body weight fell 15.0%, total fat mass fell 19.3%, visceral fat fell 27.4%, and total lean body mass fell 9.7% [12].

Lean mass went down in absolute terms, but as a share of total body mass it went up by three percentage points [12]. That is the usual pattern with substantial weight loss by any method. It is also why conversations about protein intake and resistance training come up so often around these medicines - a topic for you and a healthcare provider, not for a website.

So how does semaglutide work, in one paragraph?

Semaglutide is a modified copy of GLP-1 that survives in the body for about a week because a fatty tail keeps it bound to albumin and a swapped amino acid keeps DPP-4 from cutting it. Once free, it activates GLP-1 receptors that amplify insulin only when glucose is high, suppress glucagon, slow the stomach in the first hour after eating, and - most importantly for weight - reach specific brain regions that register fullness.

The benefits and the side effects come from the same switch. Understanding that makes the slow dose escalation, the nausea, the early fullness and the pre-surgery questions all make sense as one story rather than a list of unrelated facts.

Sources

Questions people ask

Is semaglutide the same as a natural hormone?

Almost. FDA labeling describes semaglutide as a GLP-1 analog with about 94% sequence homology to human GLP-1. Three deliberate changes to the molecule stop it from being destroyed within minutes and let it last about a week.

Does semaglutide work mainly on the stomach or on the brain?

Research points mostly to the brain. In one randomized study, people on semaglutide 2.4 mg ate 35% less at a free-access lunch, while stomach emptying at that point was barely different from placebo.

Can semaglutide cause low blood sugar by itself?

The label says semaglutide stimulates insulin and lowers glucagon in a glucose-dependent way, so the effect eases off as glucose falls. The label does warn that combining it with insulin or an insulin secretagogue raises the risk of hypoglycemia.

Why does semaglutide cause nausea?

The brainstem area where GLP-1 drugs create fullness, the area postrema, is also the brain's nausea trigger zone. Slowed stomach emptying in the first hour after a meal adds to it. The label's slow dose escalation exists specifically to reduce these gastrointestinal reactions.

Does semaglutide get into the brain?

Not broadly. Research suggests semaglutide does not cross the blood-brain barrier the way a small molecule would. It reaches specific sites called circumventricular organs, including the area postrema, where the barrier is naturally leaky.

Why do doctors start at a dose that is described as not effective?

Because the starting dose exists to let your body adjust. The Ozempic injection label states plainly that the escalation schedule is there to reduce the risk of gastrointestinal adverse reactions. For the tablets, the label goes further and says the 3 mg Rybelsus and 1.5 mg Ozempic starting doses are not effective for glycemic control.

Does semaglutide speed up your metabolism?

That is not the main mechanism described in the labeling or the mechanism literature. The dominant effects are reduced food intake, glucose-dependent insulin release, glucagon suppression and slowed early gastric emptying.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.